Latest news with #SohiniDas
&w=3840&q=100)
Business Standard
2 hours ago
- Automotive
- Business Standard
TaMo eyes 40% CV, 16% PV market share; EV biz hits Ebitda breakeven
Tata Motors targets 40% share in CVs and 16% in PVs by FY27, plans major EV investments and demerger of vehicle businesses by end-2025 premium Sohini Das Anjali Singh Mumbai Listen to This Article Tata Motors is setting its eyes on gaining market share across its passenger vehicle (PV) and commercial vehicle (CV) businesses — 40 per cent share in CVs and a 16 per cent share in PVs by 2027. Meanwhile, it has already achieved EBITDA breakeven in its electric vehicle (EV) business at 1.2 per cent (up 830 bps), ahead of its FY26 target. The company is already a market leader in CVs with a 37.1 per cent share in FY25, but in PVs it aims to go past its Korean peer Hyundai Motor India with a long-term target of 18–20 per
&w=3840&q=100)
Business Standard
4 days ago
- Automotive
- Business Standard
Rare earth crisis: Indian firms hopeful as world presses panic button
With China tightening rare earth exports, Indian firms eye domestic incentives and stockpiling, as global automakers and medical device makers face rising supply fears Shine Jacob Sohini Das Chennai Listen to This Article With global automobile majors raising concern over rare earth elements and the magnet crisis owing to export curbs by China, auto firms in India are putting on a brave face and expecting a solution soon. This is because the government is considering fiscal incentives for domestic production and increasing long-term stockpiles of rare earth magnets. At present, around 30 applications from India are stuck at various stages of approval, and that is threatening production halts and inventory depletion. 'Some European majors like Volkswagen have got permits. However, no Indian player has received clearance so far. We expect a solution soon,'
&w=3840&q=100)
Business Standard
15-05-2025
- Business
- Business Standard
Piramal Pharma expects single-digit growth in FY26 amid uncertainties
PPL projects a muted FY26 due to global headwinds but aims to double its India consumer health business turnover to Rs 2,000 crore by FY30 through scale and expansion Sohini Das Mumbai Listen to This Article Piramal Pharma (PPL), which posted a 12 per cent revenue growth for 2024–25, expects to grow in single digits in the current fiscal with a muted EBITDA. The company has a presence across contract development and manufacturing, complex hospital generics, and a consumer health business in India. Speaking to Business Standard, Nandini Piramal, Chairperson, PPL, said that FY26 is going to be a 'muted year' as there are a lot of uncertainties and it is important to watch out for macro factors like trade deals and tariff environments. PPL posted a 12 per cent rise in revenues to Rs 9,151
&w=3840&q=100)
Business Standard
12-05-2025
- Business
- Business Standard
US President Donald Trump's drug price slash could sting Indian pharma
Up to 80% US price cuts may squeeze margins, push up innovator drug costs Premium Sohini Das Mumbai Listen to This Article US President Donald Trump signing an executive order (EO) to bring the prices of prescription drugs in America in line with those paid by comparable nations is likely to have a two-pronged impact on India. First, multinational firms may look to raise drug prices in other markets, including India, thereby affecting Indian patients. Second, Indian drug exporters are expected to face pricing pressure in the US in the medium term. On May 11, Trump announced plans to sign what he called 'the most consequential EO in US history', aiming to reduce prescription drug and pharmaceutical (pharma) prices in the US
&w=3840&q=100)
Business Standard
04-05-2025
- Business
- Business Standard
Medicines are just one part of the solution: Zydus' Sharvil Patel
Zydus MD Sharvil Patel says the company is going beyond pharma into med-tech, diagnostics, and rare diseases, aiming for a global footprint while retaining India as the manufacturing hub Premium Sohini Das Listen to This Article Ahmedabad-based Zydus Lifesciences has recently forayed into medical devices and companion diagnostics. In a virtual interaction with Sohini Das, Zydus MD Sharvil Patel says medicines are only a part of the solution. Edited excerpts: You have recently forayed into med-devices. What is your game plan? When we looked at our next 10–15 years' strategy, we changed our name from a pharmaceutical company to a life-sciences organisation. We would like to play a larger role beyond pharmaceuticals alone, where we can offer better value to patients in a more holistic manner. Medical devices, companion diagnostics, early diagnostics — these are areas
